BCL2 and neoplasm: At the same time, pronounced proliferative activity (nuclear Kі-67 expression in 78.4±4.6% of tumor cells), mutant р53 expression (nuclear expression in 92% of cases), and hyperproduction of anti-apoptotic Bcl-2 protein (cytoplasmic expression) were observed in all cases (Figure 1).